Acetazolamide Sodium
The injectable sodium salt form of acetazolamide, used when oral administration is not possible or a faster onset of action is needed. It has the same carbonic anhydrase inhibiting properties as oral acetazolamide and is used in acute glaucoma, intracranial hypertension, and certain fluid-overload conditions. Like the oral form, it increases urine output and can lower potassium levels with prolonged use.
น้ำหนักโมเลกุล
244.2000 g/mol
TPSA
127.00 Ų
ด้านการรักษา
กลไกการออกฤทธิ์
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
โครงสร้าง 2 มิติ
Cite this structure
Embed this structure
SMILES
CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+]
InChI
InChI=1S/C4H6N4O3S2.Na/c1-2(9)6-3-7-8-4(12-3)13(5,10)11;/h1H3,(H3,5,6,7,9,10,11);/q;+1/p-1
Molecular Formula
C4H5N4NaO3S2
HBD / HBA
2 / 7
พันธะที่หมุนได้
2
อะตอมหนัก
14
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
คำถามที่พบบ่อย
The injectable sodium salt form of acetazolamide, used when oral administration is not possible or a faster onset of action is needed. It has the same carbonic anhydrase inhibiting properties as oral acetazolamide and is used in acute glaucoma, intracranial hypertension, and certain fluid-overload conditions. Like the oral form, it increases urine output and can lower potassium levels with prolonged use.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Acetazolamide Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200814. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 13290219. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
ข้อจำกัดความรับผิดชอบทางการแพทย์
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="acetazolamide-sodium"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/acetazolamide-sodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/acetazolamide-sodium/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/acetazolamide-sodium/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="acetazolamide-sodium"></drugfyi-drug>